LTRN ▼ -1.3% - Lantern Pharma Inc. $LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP?284 Treatment Patent in Aggressive B?Cell Lymphomas Lantern Pharma secured a U.S. patent allowance for LP-284, its experimental treatment for aggressive B-cell lymphomas, but shares fell 1.3% today despite the intellectual property milestone. The decline suggests investors may have already priced in the patent news or were expecting stronger clinical or commercial announcements to move the stock higher. 22-SEP-2026 07:47 AM ET